After being approved in Japan in 2013, the selective adenosine A 2A receptor antagonist was given the OK as an add-on to levodopa/carbidopa treatment in adults with Parkinson disease.
from Front page feed https://ift.tt/34ufOSf
from Front page feed https://ift.tt/34ufOSf
Comments
Post a Comment